Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?